Pilbara Minerals (PLS Group)

Phase A — Understand the business

Company Overview

PLS Group (renamed from Pilbara Minerals in November 2025; still ASX:PLS) is Australia's largest pure-play, hard-rock lithium producer and, by most reckonings, the largest independent (non-major-diversified) spodumene miner in the world. It does one thing: mine hard-rock ore at the 100%-owned Pilgangoora operation in Western Australia's Pilbara region, concentrate it into spodumene concentrate (SC ~5.2–6.0% Li₂O), and sell it — overwhelmingly to Chinese and Korean lithium-chemical converters who turn it into the lithium carbonate/hydroxide that goes into EVEnterprise valueWhat it would cost to buy the whole company: its market value plus its debt, minus the cash you would get with it. Often very different from market cap. and grid-storage batteries.

What it sells and to whom. The product is a bulk mineral concentrate, priced off published SC6 (6% Li₂O) benchmarks (Fastmarkets / Platts / SMM), grade-adjusted, sold CIF China. The customer roster is a consortium of offtakers rather than a spot book: POSCO, Ganfeng Lithium, General Lithium, Yibin Tianyi, Chengxin Lithium, and Sichuan Yahua. Representative terms: Yahua takes 100kt/yr in 2025–26 (+60kt option); Yibin Tianyi up to 75kt/yr over five years; Ganfeng an incremental 100kt/yr 2027–30. These are volume-committed but price-floating — the contracts lock offtake, not price, so PLS carries essentially full commodity-price exposure. That is the single most important structural fact about this business.

Contract structure / concentration. No take-or-pay price protection; revenue is ~100% one product (spodumene) sold into one end-market (batteries) that is ~itself concentrated in China's conversion complex. There is a partial downstream hedge via the POSCO joint venture (a lithium-hydroxide plant in South Korea; PLS holds 18% with a call option to 30%) and the Calix mid-stream demonstration plant (a world-first electric spodumene calciner at Pilgangoora), but both are small relative to the mining P&L today.

Why it exists / the pitch. PLS is the highest-liquidity, cleanest-balance-sheet way to express a bullish lithium view in listed equity: one asset, one commodity, tier-1 jurisdiction, low on the cost curve, ~A$1.5B net cash, no gold/iron-ore/oil to muddy the read. That purity is the whole appeal — and the whole risk.

Supply Chain

Named end-to-end (this lens fails if it stays generic):

Upstream inputs → PLS. Diesel/grid power (WA), reagents, grinding media, mining contractors, and a new 5Mtpa crushing + ore-sorting facility built under P680 that replaced the previously contracted crushing (a vertical-integration step that lowered unit cost and de-risked a single-contractor chokepoint). Ore is mined from the Pilgangoora pegmatite; PLS also holds tantalite as a by-product credit.

PLS → concentrate → converters (the core chain). Pilgangoora ore → Pilgan plant + Ngungaju plant (concentrators) → SC5.2–6.0 spodumene concentrate → shipped CIF China/Korea → converters:

• POSCO (Korea) — strategic partner + JV counterparty (hydroxide, Gwangyang).
• Ganfeng Lithium (China, HK:1772) — offtaker + proposed conversion-JV partner.
• Yibin Tianyi, Chengxin Lithium, Sichuan Yahua, General Lithium (China) — merchant converters.

Converters → cathode → cells → OEMs. Those converters feed the cathode makers (many CATL/BYD-aligned) and ultimately cell makers (CATL, BYD, LG, Samsung SDI, Panasonic) and the EV/ESS OEMs. PLS sits two-to-three steps upstream of the battery and roughly four steps upstream of the car — it never sees the OEM directly today.

Chokepoints / single-source dependencies (the real risk map):

1. China conversion concentration. The overwhelming majority of the world's spodumene-to-chemical conversion sits in China. PLS's realised price and even its ability to move tonnes is hostage to Chinese converter utilisation and inventory policy — the 2023–24 destock crushed the price precisely through this node.
2. Single producing asset. Until Colina (Brazil) is built, ~100% of production is Pilgangoora. One permit dispute, one mill outage, one WA-specific shock = the whole company.
3. Shipping/logistics through Port Hedland — standard WA bulk-export exposure (cyclones, congestion), not company-specific.

The Colina (Brazil) project and the POSCO/Calix downstream steps are deliberate moves to widen this chain — a second orebody in a second jurisdiction and a foothold in conversion — but as of mid-2026 the chain is still "one mine → China."

Competitive Advantages (moats)

Lithium mining is, at the rock level, a commodity — there is no brand, no switching cost, no network effect. A tonne of SC6 from Pilgangoora is fungible with a tonne from Wodgina. So the moat question reduces to two durable things, and PLS scores well on both:

1. Cost-curve position (the only moat that matters in a commodity). Pilgangoora is a large, high-grade, long-life hard-rock deposit and sits in roughly the second-lowest-cost tier of the global hard-rock cost curve, behind only Greenbushes. June-2025-quarter FOB unit cost ~A$397/t; Q3-FY26 FOB A$520/t (US$362/t) at higher stripping. For comparison, Greenbushes ~A$325/t, Mt Marion ~A$459–708/t, Wodgina ~A$441/t. Being low on the cost curve is what let PLS survive the trough with net cash intact while higher-cost peers bled or curtailed — the durable advantage is staying power through the cycle.

2. Scale + tier-1 jurisdiction + balance sheet. ~1Mtpa nameplate post-P1000 makes it one of the biggest single hard-rock operations globally; WA is a AAA mining jurisdiction (rule of law, no expropriation risk — contrast Zimbabwe's export ban or Chile's nationalisation history); and ~A$1.5B net cash gives it the optionality to counter-cyclically expand and acquire (Latin Resources was bought at the bottom, in scrip) while rivals defend. That is a real, if soft, moat: the ability to be the consolidator, not the consolidated.

Bargaining power is honestly weak-to-balanced. PLS needs the Chinese converters more than any single converter needs PLS (the buyer set is more concentrated than the seller set globally, and China can flex domestic + African supply). The consortium-offtake model is partly an attempt to manufacture bargaining power through diversification of buyers. The downstream JV/mid-stream moves are the explicit strategy to escape price-taking — capture conversion margin and reference a hydroxide price rather than a concentrate price. Until those scale, PLS is a price-taker with a great cost position, which is a good place to be in a commodity but not a fortress.

Segments

PLS is effectively a single-segment, single-product, single-geography business today, so a classic segment breakout doesn't apply — and no our figures exists to source one (n/a at the reported-segment level). The meaningful decomposition is by asset and by downstream stake:

• Pilgangoora (WA) — ~100% of revenue and all EBITDA. Two concentrators: Pilgan (the growth engine, expanded via P680/P1000) and Ngungaju (~200ktpa, the swing plant — placed on care-and-maintenance in the trough to protect margin, restarting July 2026 as prices recover). The Ngungaju on/off is management's clearest expression of cost discipline: cut the highest-marginal-cost tonnes when prices are low, restore them when the price rewards it.
• Colina / Salinas (Brazil) — development-stage, from the Latin Resources all-scrip acquisition (US$369M / ~A$560M, completed Jan 2025). Zero revenue today; the growth/diversification option. Renamed Colina.
• POSCO JV (Korea, 18%, option to 30%) — equity-accounted; contributed a loss in FY25 as the hydroxide plant ramped ([research on FY25 underlying adjustments below]).
• Mid-stream / Calix (Pilgangoora, JV) — demonstration-scale, pre-commercial.

Trend: the segment story is one of deliberate widening — from a single WA mine toward (a) a second orebody in the Americas and (b) two steps of downstream integration — funded off the trough balance sheet. It is decelerating as a pure miner (mining is mature/optimising) and early-accelerating as a would-be integrated lithium-chemicals business, but the latter is years and small dollars from mattering to the P&L.

---

Phase B — Measure performance

Earnings Result (latest print)

The tape tells a violent V. Three consecutive data points frame it:

Sources:.

Read of the latest print (Q3 FY26, Mar-2026 quarter). This is the quarter the thesis turned. Revenue A$567M was a record, up 52% QoQ, on record production of 232kt and a sharply higher realised price as spodumene pushed back above ~US$1,000/t. Unit FOB fell 11% QoQ to A$520/t despite higher capitalised waste stripping (i.e. underlying operating cost fell even more) — textbook operating leverage: volumes up, unit cost down, price up, so the cash margin exploded +178% to A$461M and cash built A$500M in a single quarter to A$1,455M.

Guidance. FY26: 820–870kt production, FOB A$560–600/t, capexCapital expenditureMoney spent on long-lived things — buildings, machines, servers — rather than on running costs. A$303–330M. Tone shifted decisively from "defend the balance sheet through the winter" (FY25) to "restart Ngungaju, resume the mid-stream, look at deals" (FY26) — CEO explicitly framing the price move as supply-risk-driven and warning that "current pricing does not support the investment required to build the next wave of supply".

Balance-sheet flags. Overwhelmingly positive: net cash ~A$1.5B, and post-quarter a US$600M 6.875% senior unsecured note due 2031 (settled 22-Apr-2026) that terms out the balance sheet with long-tenor, unsecured, covenant-light debt. This is a company adding dry powder near a cyclical low, not shoring up a hole. Watch capitalised stripping (it flatters reported unit cost vs. true all-in), and the equity-accounted POSCO JV losses (below).

Statutory vs. underlying (do not gloss). FY25 statutory was a A$196M loss; "underlying" strips the fair-value movement on the POSCO 18%→30% call option (−A$39.5M), the equity-accounted POSCO JV loss (−A$46.7M), and mid-stream project costs (A$19.9M). The gap is real cash-adjacent drag from the downstream ambitions, not one-off noise — the integration strategy is currently a cost, not yet a return.

Earnings Calls (sentiment trend)

No transcripts/ on the shelf; sentiment is reconstructed from reported calls/quotes across FY25→Q3-FY26.

Arc of tone, last ~4 calls:

• FY25 / mid-2024 calls (trough): defensive. Language: "cost discipline," "capital management," "balance-sheet strength," "care and maintenance," dividend cancelled. Management's job was to survive and be believed to survive.
• Sep-25 quarter: first thaw — "20% increase in realised pricing," revenue +30% QoQ to A$251M; tone turns from survival to opportunity.
• H1 FY26 (Feb-26): confidence returns — "+241% EBITDA," "return to profit," but still "prioritising financial flexibility… no interim dividend." Disciplined, not euphoric.
• Q3 FY26 (Apr-26): most assertive yet — "record results," restart Ngungaju, resume mid-stream, "looking for deals," and a supply-side thesis: the price rally is rational because "current pricing does not support the next wave of supply," swing supply "should act rationally".

Recurring phrases: "disciplined capital allocation," "through the cycle," "low on the cost curve," "financial flexibility," "downstream/mid-stream," "consortium of partners." Things they stopped saying: "care and maintenance" (as a defensive necessity), "preserving cash" as the dominant frame. The pivot word is "deals" — a net-cash miner at a cyclical inflection openly hunting M&A is a tell about where management thinks we are in the cycle.

Net: management's credibility is high precisely because they under-promised in the trough (kept net cash, cut Ngungaju, cancelled the dividend early) and are now visibly vindicated. The risk in the sentiment is the opposite one — that a vindicated management over-expands into the recovery (see Lens 9/13).

Comps

Peer table — global lithium producers.

How to read it. On trailing EBITDA PLS looks expensive — but that's an artifact of a trough denominator (FY25 EBITDA A$97M). At A$16.2B mcap the market is capitalising a normalised or recovering EBITDA, i.e. it is already pricing the recovery, not the trough. Against ALB (19.8x) and SQM (12.3x) on trailing, and given PLS's superior cost position but zero brine and no downstream scale yet, PLS is not cheap on any spot metric — it is priced as a high-quality, high-beta recovery call. The honest comp statement: PLS trades at a scarcity/purity/balance-sheet premium; the valuation is a bet on the lithium price and the volume ramp, not on a cheap multiple.

Stock-Price Catalysts (what moves this stock >5%)

The 5-year tape is one of the most extreme in the ASX large-cap complex — a full boom→bust→recovery. Range: A$1.14 (Jun-24 multi-year low) → A$6.81 (52-wk high) → A$5.04 (Jun-26). Up >200% in six months into Dec-25.

What actually moves it (pattern):

1. The lithium/spodumene price, first and foremost. PLS is a near-perfect price-beta instrument. −60% YoY moves in lithium mapped straight into the equity in 2023–24; the 2025–26 doubling of spodumene drove the +200%.
2. China supply-side shocks. The single-day ~+20% move came off a "surprise supply disruption in China" (CATL's Jianxiawo lepidolite mine suspension) plus PLS's own cost/production beat. Zimbabwe's raw-lithium export ban (accelerated to Feb-2025) is the other supply catalyst. The market reacts violently to anything that tightens the concentrate balance.
3. PLS-specific: production/cost beats, guidance changes, and capital events. Ngungaju care-and-maintenance (down-move), FY25 guidance cut, the Latin Resources scrip deal, the US$600M notes, and the dividend cancellation all moved the stock — but less than the commodity does.
4. Short-covering mechanics. As the ASX's most-shorted stock (~20–21% at peak), PLS has a reflexive up-move amplifier: good lithium news forces covering, which exaggerates rallies (and the reverse on the way down).

What this reveals: the market does not primarily trade PLS on execution or valuation — it trades it as the liquid listed proxy for the spodumene price and for China supply headlines. That is the key to sizing any position: your P&L will be dominated by the lithium price and the short-positioning, not by whether PLS beat FOB cost by A$20/t.

---

Phase C — Judge people & books

Management

CEO — Dale Henderson (MD & CEO since July 2022; previously COO). Total FY comp ~A$4.5M (32.7% fixed / 67.3% variable-equity), direct ownership ~0.065% of shares. Chair — Anthony Kiernan (long-tenured; board avg tenure ~7.2 yrs vs management ~2 yrs).

1. Track record. The defining call of Henderson's tenure was navigating the 2023–25 lithium collapse without impairing the balance sheet — early dividend suspension (Sep-2023), Ngungaju to care-and-maintenance, aggressive unit-cost reduction, and completing the P680/P1000 growth capex through the trough so PLS emerged with ~1Mtpa capacity and net cash exactly as the price turned. In a sector where several peers curtailed, raised distressed equity, or blew up, that is a genuinely strong, quantified, cycle-tested record.
2. Skin in the game. ~0.065% direct is low in absolute terms (Henderson is a professional manager, not a founder-owner), though heavily equity-weighted comp aligns him with the share price. Not a red flag for a company this size, but not founder-level alignment either.
3. Capital allocation. Mixed-but-defensible. Pros: counter-cyclical M&A in scrip (Latin Resources bought near the bottom without cash outflow); disciplined dividend policy (cut when it had to, refusing to reinstate prematurely — H1-FY26 interim withheld despite the profit swing); terming out debt at a sensible moment. Cons: the downstream bets (POSCO JV, Calix mid-stream) are value-destroying today — the POSCO 18% stake generated a A$46.7M equity-accounted loss in FY25 and the call-option fair value another −A$39.5M. The strategy may be right long-term but it is currently a drag, and the market is not yet paying for it.
4. Red flags. None material found. No related-party dealing, no promotional stock behaviour, no accounting controversy surfaced (Lens 10). Comp is in-line for an A$16B miner. The soft concern is strategic, not integrity: a vindicated management team openly "looking for deals" into a recovering price is where value-destructive top-of-cycle M&A historically happens (see Lens 13).
5. Archetype. Professional operator, not founder-owner. For this stage — a scaled producer optimising a mature asset and cautiously integrating downstream — that is the right archetype. The risk it implies: professional managers of cyclical miners are structurally tempted to grow the empire in the up-cycle. The board (long-tenured, independent chair) is the check.

Verdict on people: above-average, cycle-tested, credible. The operator is not the risk in this name — if anything the operator is a mild positive. The risk is the commodity and the capital-allocation temptation of the recovery.

Forensic Red Flags

Acting as a forensic analyst. PLS is a relatively clean read for a miner, but three things warrant scrutiny:

1. Statutory vs. underlying gap (the main one). Management's headline "underlying" numbers exclude real drags: POSCO JV equity losses (−A$46.7M FY25), the POSCO call-option fair-value swing (−A$39.5M), and mid-stream costs (A$19.9M). These are recurring consequences of the downstream strategy, not one-offs — treating them as "underlying adjustments" flatters the operating story. Read the statutory loss (A$196M FY25) as the truer figure.
2. Capitalised waste stripping. Q3-FY26 FOB fell to A$520/t "reflecting… increased capitalised waste stripping" — i.e. some cost was moved to the balance sheet, understating reported cash unit cost vs. true all-in sustaining cost. Standard mining accounting, fully disclosed, but it means quoted FOB flatters the real per-tonne economics; watch the stripping ratio and deferred stripping asset.
3. Impairment risk on Colina/Latin Resources. ~A$560M of scrip bought a development-stage Brazilian asset at a lithium-price level that has since whipsawed. If prices roll over again, the carrying value is a candidate for write-down. No impairment taken to date per available disclosure, but it is the balance-sheet item most exposed to a renewed downturn.; not yet flagged by the company.

Divergence checks: cash flow vs. earnings — Q3-FY26 cash built A$500M on record margin, so cash conversion is currently strong (not a diverging-CF red flag). Receivables/inventory outrunning revenue — no evidence surfaced; the swing-plant model actually pulls inventory down in the trough. SBC flattering non-GAAP — comp is equity-heavy but the adjustments above are the bigger non-GAAP lever than SBC.

Regulatory findings (required sub-section).

• SEC (EDGAR LR + AAER): — zero findings. PLS has no CIK; it is not an SEC registrant, so no EDGAR enforcement search is possible. Not a clean bill from a US regulator — simply outside its jurisdiction.
• Non-SEC / home-market: web search surfaced no material ASIC or ASX enforcement action, fine, or consent decree against Pilbara Minerals/PLS Group. No going-concern, no restatement.
• 10-K Item 3 equivalent: PLS files under ASX/Australian rules (Annual Report + Corporations Act), not a 10-KForm 10-KA company’s audited annual report to the US regulator. The most complete thing it publishes., so there is no Item 3 to quote. The material legal/social exposure disclosed and reported is native-title / Traditional Owner matters — Pilgangoora sits on Nyamal and Kariyarra Country. (The A$1.8B Pilbara Traditional-Owner compensation matter widely reported is a Yindjibarndi vs. Fortescue case in the broader Pilbara, not a PLS proceeding — do not misattribute it to PLS.) Native-title and heritage risk is a real, sector-wide WA operating exposure but no company-specific material adverse finding against PLS was sourced.
• Conclusion: No material regulatory or legal findings against PLS — verified via SEC EDGAR EFTS (no CIK, N/A), web search (ASIC/ASX/other), and the absence of any reported restatement or enforcement, as of 2026-07-06. Standard WA native-title/heritage exposure applies but is not a specific enforcement matter.

---

Phase D — Project & stress-test

Forward Projection (FY26 / FY27 / FY28 EPS)

No our model created (per unattended --watchlist rules). All figures with arithmetic; inputs.

PLS's earnings are a price × volume × (price − cost) margin function with enormous operating leverage — small moves in the realised spodumene price swing EPS by multiples. So this is a scenario model, not a point estimate. Shares ~3.0B. All in AUD.

Volume path (relatively knowable):

• FY26 guidance 820–870kt (midpoint ~845kt).
• FY27 with Ngungaju restarted + P1000 ramped: ~900–1,000kt.
• FY28 steady-state at/near nameplate: ~1,000kt.

Price scenarios (the swing variable) — SC6 realised, USD/t, using external forecasts as anchors:

Illustrative base-case EPS bridge: FY27 ~950kt × US$1,150/t ≈ US$1.09B revenue ≈ A$1.66B (at ~0.66 AUDUSD). Cash cost ~A$580/t × 950kt ≈ A$0.55B → cash margin ≈ A$1.11B; less ~A$0.2B D&A/JV drag/corporate/interest ≈ pre-tax ~A$0.9B; ~30% tax ≈ NPAT ~A$0.63B ÷ 3.0B shares ≈ A$0.21 EPS. `/ above.]

• Bull FY27 (US$1,500, ~1Mtpa): margin ~A$1.7B → NPAT ~A$1.0–1.1B → EPS ~A$0.35.
• Bear FY27 (US$750, some volume curtailed): margin compresses toward cash-cost breakeven on the marginal tonnes → NPAT near-zero to small loss → EPS ~A$0.00–0.03.

What the model shows: at A$5.04, the market is capitalising something like the base-to-bull path (a base EPS ~A$0.21 → ~24x; bull ~A$0.35 → ~14x). The downside is not a modest de-rate — it is EPS collapsing to ~zero in the bear case, because a low-cost miner's earnings are convex to price: the cost floor is fixed, so the whole price move drops to the bottom line, in both directions. This is a call option on the lithium price, not a bond. (No Brier forecast logged per loop rules.)

Bull vs Bear

Bull case (narrative). The lithium winter is over and it ended for structural, not cyclical, reasons. Two-to-three years of sub-incentive prices deferred a wave of supply exactly as demand inflected — ESS shipments alone were revised +60% to 750GWh for 2026, EV penetration keeps compounding, and the marginal new mine takes 10–17 years from discovery. Into that, PLS is the lowest-cost, largest, cleanest independent, sitting on ~A$1.5B net cash and ~1Mtpa nameplate, with a management team that just proved it can compound through a trough. As the price normalises toward incentive levels (US$1,300–1,800 spodumene), PLS's convex margin means EPS multiplies, the dividend comes back, the short base (which fuelled the down-move) keeps covering, and the downstream/Colina options start to pay. You are buying the best house on the best street in a commodity that the energy transition cannot do without.

Bear case (2–3 permanent-impairment risks).

1. The recovery is a China-restock head-fake, not a structural deficit. The 2025–26 rally leaned heavily on supply shocks (Jianxiawo suspension, Zimbabwe ban) that can reverse — Jianxiawo is flagged to potentially restart H2-2026. If Chinese lepidolite + African + brine supply comes back while EV growth disappoints, spodumene re-tests the trough and PLS EPS goes to ~zero. The price has already run 5x — you are buying after the easy money.
2. PLS is a structural price-taker in a China-controlled midstream. No pricing power, ~100% concentrate to Chinese converters, offtakes lock volume not price. A determined China (which is long its own lithium supply security) can keep the concentrate price below the level that rewards ex-China miners.
3. Top-of-cycle capital misallocation. A net-cash, vindicated management "looking for deals" into a recovery is the classic setup for value-destructive M&A and over-expansion (adding the next wave of supply that caps the very price they need). The downstream bets already lose money.

Pre-mortem (18 months out, thesis broke — what happened?). Most likely: spodumene rolled back to ~US$700–800 as Chinese lepidolite restarted and a couple of African/brine projects ramped into still-soft EV demand; PLS's realised price halved, Ngungaju went back to care-and-maintenance, the Colina carrying value was written down, no dividend returned, and the stock round-tripped from ~A$5 toward ~A$2.50 as the shorts came back. Second scenario: the commodity held but PLS overpaid for an acquisition at the top and diluted/levered the pristine balance sheet away.

Are multiples too high? On any spot metric, yes — PLS is priced for recovery, not for the trough. The bull rebuttal is that spot metrics are the wrong lens for a convex, mid-cycle cyclical; the bear rebuttal is that "it's cyclical" is what buyers of every top-of-cycle miner tell themselves.

Contrarian view (what the market refuses to see). The consensus debate is "is the lithium recovery real?" The under-appreciated point is that it may be too real for PLS's own good: if prices spike to incentive levels, they summon the deferred supply (Chinese lepidolite, African, Latin American brine, direct-lithium-extraction) and cap the up-cycle faster and lower than in prior commodity cycles, because the world wants cheap lithium and has many ways to make it. The most dangerous number for a low-cost lithium miner is not a low price — it's a high price that lasts long enough to build its own gravedigger. PLS's real edge (cost position + balance sheet) matters most in the next down-cycle, which is precisely when the market won't want to own it.

Devil's Advocate (short-seller)

Dismantling the bull case. PLS was the ASX's most-shorted stock for good structural reasons, and most of them still hold:

• What structurally breaks the money-machine: a return to sub-incentive spodumene prices. PLS makes ~100% of its money from one floating-priced commodity; there is no annuity, no contract floor, no second product. The entire equity is a leveraged bet on a number PLS does not control.
• Revenue concentration → China. Concentrated in Chinese converters who are themselves building/controlling upstream supply (domestic lepidolite, African JVs, offtakes everywhere). China's structural incentive is cheap lithium; PLS's is expensive. The buyer is the adversary.
• Why the moat is weaker than bulls think. "Low on the cost curve" is real but it is a relative advantage that only pays in a downturn — in an up-cycle every marginal producer is profitable and PLS's edge compresses to nothing. And the cost curve itself is falling as ore-sorting/DLE/African scale mature. Second-lowest-cost is not a fortress; it is a survival trait, and survival is already in the price at A$16B.
• Most dangerous underestimated competitor: Chinese lepidolite + African hard-rock (Zimbabwe, Mali). Bulls treat the 2025 supply cuts as permanent; they are policy/price-driven and reversible. CATL's Jianxiawo restart (flagged H2-26) alone could re-loosen the balance.
• Worst capital-allocation exposure: the downstream JV/mid-stream losing money now (−A$86M+ of FY25 drag between the JV loss and option), plus a A$560M development asset (Colina) bought in scrip that is a live impairment candidate, plus an openly acquisitive posture into a recovery.
• What must hold for A$5.04: spodumene sustaining ~US$1,100–1,300+ and the ~1Mtpa volume ramp delivering and no value-destroying deal and the shorts not re-engaging. Several independent things, each price-dependent.
• −20–30% growth/price disappointment: because earnings are convex, a ~25% realised-price miss doesn't cut EPS ~25% — it can cut it 50–80%+ (fixed cost floor), and the multiple also de-rates as the recovery narrative breaks. That's the double-whammy that took it from A$6.81 territory back toward A$5, and could take it lower.
• Single scenario that permanently impairs: it doesn't — Pilgangoora is a real, long-life, low-cost orebody; PLS survives almost any price. "Permanent impairment" is the wrong frame. The right short frame is valuation + timing: you are short a great asset at a recovered price with the easy 5x already gone and reversible supply cuts holding it up.

Short-seller's one-liner: Great rock, great balance sheet, wrong entry — the trade was A$1.14, not A$5.04; from here you're paying a scarcity premium for a price-taker whose own success calls forth the supply that ends the rally.

Management Questions (ordered by information value)

1. What sustained spodumene price do you actually underwrite for a growth/M&A decision — and at what price do you pause P1000 or re-mothball Ngungaju? (The whole thesis is your read of the price floor.)
2. You are openly "looking for deals." What return hurdle and what price deck govern acquisitions, and how do you avoid buying the next wave of supply that caps the price you need?
3. The downstream (POSCO JV, Calix mid-stream) lost ~A$86M+ in FY25. What is the timeline and IRR at which conversion becomes value-accretive, and at what point do you cut it if it doesn't?
4. Colina (Brazil): at what spodumene price is FID economic, what is the capex, and what is your impairment trigger on the carrying value if prices fall?
5. How do you break the structural price-taker position vs. Chinese converters — is downstream integration genuinely capable of moving you to a hydroxide-referenced margin at scale, or is it a hedge in name only?
6. What is your true all-in sustaining cost including capitalised stripping and sustaining capex — not just quarterly FOB — and where does it sit on the cost curve after peers' ore-sorting/DLE gains?
7. Dividend: what specific cash/price threshold reinstates it, and how do you weigh returns to shareholders against the "deals" ambition?
8. How exposed are realised prices if CATL's Jianxiawo restarts and African supply ramps in H2-26 — what's your concentrate balance view for 2027?
9. What is your customer-concentration and counterparty risk to the Chinese converter complex, and what happens to offtake volumes if Chinese utilisation drops again?
10. Ngungaju has been on/off twice. What is the true marginal cost of the swing tonnes, and the price band that governs the switch?
11. How do native-title and heritage obligations (Nyamal/Kariyarra) constrain future Pilgangoora expansion, and what's the cost/timeline exposure?
12. Post the US$600M 2031 notes, what is your target through-cycle net-cash/leverage range, and would you lever up for M&A?
13. What share of FY26–28 volume is contracted vs. spot, and how are the offtake price mechanisms structured (index, lag, floors)?
14. What is your grade/strip-ratio trajectory at Pilgangoora over the next 3–5 years — is the low-cost position sustainable as the pit deepens?
15. How do you think about recycling and DLE as a 2030s threat to hard-rock concentrate demand?

---